FDA Generic Labeling Rule Could Help Pfizer In Reglan Product Liability Suit
This article was originally published in The Pink Sheet Daily
Alabama Supreme Court is reconsidering its decision holding brand-name manufacturers liable for injuries caused by generics; Pfizer argues that FDA’s forthcoming proposed rule would eliminate concerns that no company could be held liable for injuries from a generic.
You may also be interested in...
Pfizer’s litigation department scored several key victories in the past year, which the company chalks up to its business approach to running cases and the teamwork of its law firms.
The pharmaceutical industry is reeling from a court ruling that found brand name manufacturers are liable for the warnings on generic versions of their products
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.